AstraZeneca Profit Misses Estimates as Sales Decline

AstraZeneca Plc said third-quarter profit fell 31 percent as sales of the Brilinta heart drug failed to offset generic competition for its best-selling medicines. The company also named a new chief financial officer.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.